Marksans Pharma FY26 Profit Jumps to ₹420 Crore; Declares ₹0.90 Dividend

HEALTHCAREBIOTECH

Marksans Pharma reported strong growth for FY26, with consolidated revenue at ₹2,950.94 crore and PAT at ₹420.06 crore. The company also recommended a ₹0.90 per share dividend.

Marksans Pharma Reports Strong FY26 Results, Recommends Dividend

Consolidated Revenue (FY26): ₹2,950.94 crore
Consolidated PAT (FY26): ₹420.06 crore

Reader Takeaway: Robust financial growth and dividend payout, offset by minor labour code cost impact.

Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.